Glibenclamide directly act on SUR1, leading to the closure of KATP channel and the normal release of insulin, improving the growth imbalance, nervous system disorders and muscle strength of some PNDM children, but may cause hypoglycemia, temporary diarrhea, tooth staining, long Q-T syndrome and other adverse reactions (Cao et al., 2020). The gene discussed is INS; the disease is Hypoglycemia.